- Pfizer Inc PFE has started dosing in Phase 2/3 trial of its oral antiviral therapy for COVID-19 in non-hospitalized, symptomatic adult patients.
- The trial would enroll 1,140 participants who will receive PF07321332/ritonavir combo or placebo every 12 hours for five days.
- PF-07321332 is designed to block the activity of a key enzyme that is needed for the coronavirus to replicate.
- Merck & Co Inc MRK and Ridgeback Biotherapeutics have started a molnupiravir Phase 3 trial in non-hospitalized patients to see if it reduces the risk of hospitalization or death.
- Related Content: Merck To Test Oral Antiviral Candidate For Post-Exposure Prophylaxis Of COVID-19 Infection
- Price Action: PFE stock is down 0.97% at $45.63 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
